ETF · real data, updated daily
IBB — Ishares Biotechnology ETF
Over the last 15 years (2011-08 – 2026-09), $10,000 invested in IBB with dividends reinvested grew to $69,408 — 13.63% a year — with a worst peak-to-trough fall of -33.61%. Past performance doesn't predict future results.
Growth of $10,000 · 2011-08 – 2026-09 · dividends reinvested
About IBB
iShares Biotechnology ETF is an exchange-traded fund that provides broad exposure to U.S.-listed biotechnology companies. The fund is designed to track a biotechnology-focused index and typically holds a diversified basket of large, mid, and smaller biotechnology names, along with select life sciences tools and services companies that support drug discovery and research. Its portfolio includes firms involved in areas such as therapeutics, genetic medicine, diagnostics, and advanced research platforms. By concentrating on the biotechnology segment, iShares Biotechnology ETF serves as a sector-specific instrument for investors seeking access to one of the most research-intensive areas of the healthcare market. The fund is used by market participants as a way to gain diversified exposure to companies developing innovative medicines and scientific technologies within the healthcare industry.
Put IBB to the test
Every tool below opens prefilled with IBB — free, no account needed.
Backtest IBB →
Full history, any date range, benchmarks, drawdowns, rolling returns.
Would IBB survive 2008? →
What actually happened to it in the crisis — real drawdown and recovery.
Project it forward →
Monte Carlo simulation of where it could go from here.
Compare IBB vs VTI →
Head-to-head against the total US market.
Replay $100/mo into IBB →
Animated growth of steady monthly contributions.
Fundamentals →
Holdings-level financials where available.
Educational use only — not investment advice. Results are hypothetical.Read full disclaimer
This tool is for educational and informational purposes only and does not provide financial, investment, tax, legal, or accounting advice. Results are hypothetical and based on historical data and assumptions that may be inaccurate. Past performance does not guarantee future results. Consult a licensed professional before making investment decisions.